# Riliprubart prefilled pen (pfp) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp

> The next catalyst for riliprubart prefilled pen (pfp), sponsored by Sanofi (SNY), is its topline data readout, Oct 2029 to Jan 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | riliprubart prefilled pen (pfp) |
| Codes | SAR445088 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Polyneuropathy, Inflammatory Demyelinating, Chronic](https://sec-api.dev/indications/polyneuropathy-inflammatory-demyelinating-chronic) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Polyneuropathy, Inflammatory Demyelinating, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06859099 (Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-10-03 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06859099

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Polyneuropathy, Inflammatory Demyelinating, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06859099 (Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-10-03 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06859099

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Riliprubart prefilled pen (pfp) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp

```bibtex
@misc{secapidev_pdufa_riliprubart_prefilled_pen_pfp_20261116,
  title        = {Riliprubart prefilled pen (pfp) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_riliprubart_prefilled_pen_pfp_20261116","title":"Riliprubart prefilled pen (pfp) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
